Home/Pipeline/SY-5609

SY-5609

Solid Tumors

Phase 1/2DiscontinuedNCT04247126

Key Facts

Indication

Solid Tumors

Phase

Phase 1/2

Status

Discontinued

Company

Syros Pharmaceuticals

About Syros Pharmaceuticals

Syros Pharmaceuticals' mission is to develop breakthrough medicines for cancer and other diseases by controlling the expression of disease-driving genes, a historically 'undruggable' target class. Its key achievement is building a proprietary gene control platform and advancing multiple candidates into clinical trials, most notably tamibarotene for RARA-positive higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). The company's strategy hinges on clinically validating its platform to unlock the therapeutic potential of modulating transcription factors, though its path is fraught with financial and clinical execution risks. Syros's future depends on demonstrating compelling efficacy and safety data to attract partnership capital or secure alternative funding.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed